Dana Yaacov-Garbeli - 11 Nov 2022 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Signature
/s/ Dana Yaacov-Garbeli
Issuer symbol
ENTX
Transactions as of
11 Nov 2022
Net transactions value
+$29,847
Form type
4
Filing time
15 Nov 2022, 15:13:24 UTC
Previous filing
09 Sep 2022
Next filing
25 Apr 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase $15,600 +30,000 $0.5200 30,000 11 Nov 2022 By A2Z Counseling Ltd. F1, F2
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase $14,247 +26,580 +89% $0.5360 56,580 14 Nov 2022 By A2Z Counseling Ltd. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.50 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 These shares are owned by A2Z Counseling Ltd. of which the Reporting Person's owns a 33.33% interest and has effective control over voting and disposition of the shares. The Reporting Person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.53 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.